Skip to search formSkip to main contentSkip to account menu

PR-104

Known as: PR104 
A non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity. Upon intravenous… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using… 
Review
2014
Review
2014
Hypoxia, a state of low oxygen, is a common feature of solid tumors and is associated with disease progression as well as… 
Highly Cited
2011
Highly Cited
2011
Recent studies indicate that interactions between leukemia cells and the bone marrow (BM) microenvironment promote leukemia cell… 
Highly Cited
2011
Highly Cited
2011
BackgroundThe phosphate ester PR-104 is rapidly converted in vivo to the alcohol PR-104A, a nitrogen mustard prodrug that is… 
Review
2010
Review
2010
PR-104, currently in phase II clinical trials, is a phosphate ester pre-prodrug which is converted in vivo to its cognate alcohol… 
Highly Cited
2010
Highly Cited
2010
PurposePR-104 is a “pre-prodrug” designed to be activated to a dinitrobenzamide nitrogen mustard cytotoxin by nitroreduction in… 
Highly Cited
2007
Highly Cited
2007
Purpose: Hypoxia is a characteristic of solid tumors and a potentially important therapeutic target. Here, we characterize the…